- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 07.11. | Teknova reiterates $39M-$42M 2025 revenue target while eyeing 20%-25% long-term growth amid operational advances | 1 | Seeking Alpha | ||
| 06.11. | Alpha Teknova GAAP EPS of -$0.08 beats by $0.01, revenue of $10.5M beats by $0.27M | 1 | Seeking Alpha | ||
| 06.11. | Alpha Teknova, Inc.: Teknova Reports Third Quarter 2025 Financial Results | 25 | GlobeNewswire (Europe) | Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million... ► Artikel lesen | |
| 28.10. | Alpha Teknova, Inc.: Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025 | 4 | GlobeNewswire (USA) | ||
| 20.10. | Alpha Teknova (TKNO) Surged Following Accelerated Demand | 2 | Insider Monkey | ||
| 01.09. | Does Alpha Teknova (TKNO) Have Meaningful Growth Opportunities? | 2 | Insider Monkey | ||
| 08.08. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.07. | Alpha Teknova files $225M mixed securities shelf | 4 | Seeking Alpha | ||
| 23.06. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 491 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 70,68 | 0,00 % | TD Cowen reiterates Hold rating on Avidity Biosciences stock at $74 | ||
| VERA THERAPEUTICS | 29,460 | 0,00 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| NUVALENT | 108,01 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 64,83 | 0,00 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,725 | 0,00 % | Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress | ||
| ARCUTIS BIOTHERAPEUTICS | 26,180 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 37,440 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 44,330 | 0,00 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| DYNE THERAPEUTICS | 20,240 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 7,320 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 197,24 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| PRIME MEDICINE | 3,795 | 0,00 % | Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock | ||
| RELAY THERAPEUTICS | 6,620 | +5,50 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 13,610 | 0,00 % | Monte Rosa Therapeutics: NBC feiert +135% nach Kaufempfehlung | Im NBC-Depot strahlen die nächsten dreistelligen Prozente: Die Aktie von Monte Rosa Therapeutics liefert nach dem Einstieg des No Brainer Club eine beeindruckende Kursrallye und schnellt +125% in acht... ► Artikel lesen | |
| INVIVYD | 2,845 | 0,00 % | Invivyd prices $125M stock offering at $2.50 per share |
ALPHA TEKNOVA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.